Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial

Mise à jour : Il y a 5 ans
Référence : EUCTR2007-002803-42

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

In contrast to other vasodilators used for the treatment of PAH, inhaled iloprost reduces pulmonary arterial pressure without affecting the systemic circulation and may be used for right heart failure.


Critère d'inclusion

  • Pulmonary arterial hypertension (PAH) is associated with poor prognosis.The most common cause of death is right heart failure. The fact that right heart failure is associated with low systemic perfusion pressures limits the systemic use of potent vasodilators in this patient population. As a consequence, no therapeutic recommendations exist for patients experiencing right heart failure in the course of PAH

Liens